SpectraCure AB (SE:SPEC)
:SPEC
Want to see SE:SPEC full AI Analyst Report?
Top Page
SpectraCure AB
(SPEC)
Select Model
Select Model
Rating:43Neutral
Price Target:
kr0.07
▼(-62.22% Downside)
Action:ReiteratedDate:04/25/26
The score is primarily pressured by weak financial performance (minimal revenue, worsening losses, and negative/free cash flow) and bearish technical trends (below major moving averages with negative MACD). A low-debt balance sheet provides some offset, but valuation is constrained by ongoing losses and no dividend signal.
Positive Factors
Low financial leverage
A low debt load relative to equity provides durable financial flexibility, reducing near-term solvency risk and enabling the company to fund R&D or clinical programs via equity or modest borrowing. This conservatism supports runway management while commercialization remains pending.
Negative Factors
Negative and worsening cash flow
Consistent negative operating and free cash flow with accelerating burn undermines self-financing ability, forcing reliance on external capital. Over a multi-month horizon this increases dilution and execution risk if fundraising windows tighten or capital costs rise.
Read all positive and negative factors
Positive Factors
Negative Factors
Low financial leverage
A low debt load relative to equity provides durable financial flexibility, reducing near-term solvency risk and enabling the company to fund R&D or clinical programs via equity or modest borrowing. This conservatism supports runway management while commercialization remains pending.
Read all positive factors
SpectraCure AB (SPEC) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr39.20M
Dividend YieldN/A
Average Volume (3M)1.15M
Price to Earnings (P/E)―
Beta (1Y)-0.58
Revenue GrowthN/A
EPS Growth-104.27%
CountrySE
Employees16
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.02
Shares Outstanding570,602,840
10 Day Avg. Volume1,242,664
30 Day Avg. Volume1,152,681
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.68
Price to Sales (P/S)0.00
P/FCF Ratio-2.66
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
SpectraCure AB Business Overview & Revenue Model
Company Description
SpectraCure AB (SPEC) is a medical technology company operating primarily in the field of cancer treatment. The company specializes in developing and commercializing innovative systems for photodynamic therapy (PDT), a minimally invasive treatment...
How the Company Makes Money
null...
SpectraCure AB Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 318.00K | 539.00K | 0.00 |
| Gross Profit | -30.14M | 9.77M | -9.22M | 3.58M | 1.39M |
| EBITDA | -24.22M | -20.42M | -20.97M | -22.27M | -20.43M |
| Net Income | -56.08M | -23.00M | -20.44M | -25.33M | -23.34M |
Balance Sheet | |||||
| Total Assets | 104.47M | 121.00M | 144.83M | 162.42M | 190.52M |
| Cash, Cash Equivalents and Short-Term Investments | 13.53M | 18.27M | 56.95M | 93.18M | 129.69M |
| Total Debt | 3.01M | 5.14M | 6.72M | 2.70M | 4.90M |
| Total Liabilities | 10.92M | 14.15M | 14.97M | 12.12M | 14.84M |
| Stockholders Equity | 93.55M | 106.86M | 129.86M | 150.30M | 175.68M |
Cash Flow | |||||
| Free Cash Flow | -24.03M | -37.10M | -34.45M | -33.08M | -27.09M |
| Operating Cash Flow | -24.03M | -21.83M | -18.68M | -22.96M | -18.60M |
| Investing Cash Flow | -19.64M | -15.28M | -15.56M | -11.35M | -8.49M |
| Financing Cash Flow | 38.92M | -1.57M | -1.99M | -2.20M | -453.00K |
SpectraCure AB Technical Analysis
Negative
0.18
Price Trends
0.09
Negative
0.12
Negative
0.15
Negative
Market Momentum
>-0.01
Positive
26.88
Positive
14.42
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SPEC, the sentiment is Negative. The current price of 0.18 is above the 20-day moving average (MA) of 0.08, above the 50-day MA of 0.09, and above the 200-day MA of 0.15, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 26.88 is Positive, neither overbought nor oversold. The STOCH value of 14.42 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:SPEC.
SpectraCure AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | kr338.80M | -1.43 | -253.54% | ― | 36.21% | 11.93% | |
44 Neutral | kr55.87M | -8.36 | ― | ― | -9.56% | 51.30% | |
43 Neutral | kr39.20M | -1.14 | -50.21% | ― | ― | -104.27% | |
43 Neutral | kr177.95M | -1.96 | ― | ― | ― | 68.59% | |
42 Neutral | kr39.04M | -2.89 | -60.56% | ― | 27.31% | 6.31% |
* Healthcare Sector Average
SE:SPEC
SpectraCure AB
0.07
-0.26
-79.20%
SE:SCIB
SciBase Holding AB
0.41
0.09
27.81%
SE:LXB
Luxbright AB
0.15
-0.61
-80.18%
SE:HEART
Scandinavian Real Heart AB
17.80
2.56
16.76%
SE:SDOS
ScandiDos AB
0.98
-0.30
-23.44%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.